Media

Orexo divests subsidiary Kibion

BONESUPPORT Announces CE-Mark of CERAMENT™|V, the First Injectable Vancomycin Eluting Bone Substitute in the Management of Osteomyelitis

Aerocrine AB responds to recent speculation in the market

HealthCap awarded SVCA’s Deal of the Year

RESULTS OF PHASE 1 STUDY OF BETALUTIN™ IN PATIENTS WITH NON-HODGKIN LYMPHOMA TO BE PRESENTED AT THE INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

Interim report January-March 2015

Aerocrine: Sales start of NIOX VERO® in Japan

New 24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv for maintenance treatment of opioid dependence

Nordic Nanovector ASA – Stabilisation notice and exercise of over-allotment option, total gross proceeds from IPO increase to NOK 575 million

Orexo to present at 2015 Nordic Life Sciences Conference